DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Dyggve-Melchior-Clausen disease — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDyggve-Melchior-Clausen disease maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dyggve-melchior-clausen disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Dyggve-Melchior-Clausen syndrome is caused by loss-of-function mutations in the gene Dymeclin (FLJ20071), identified through positional cloning in ten families. Seven deleterious mutations were found: nonsense mutations R194X, R204X, L219X, Q483X, and splice-site or frameshift mutations including K626N+92aa to stop. The gene transcript is widely distributed but abundant in chondrocytes and fetal brain. The predicted protein shows no significant homology to any known protein family, though its carboxy terminal end contains a cluster of dileucine motifs conserved across species. The authors proposed that Dymeclin may have a role in intracellular digestion of proteins, based on electron microscopy of cutaneous cells from an affected child showing dilated rough endoplasmic reticulum, enlarged aberrant vacuoles, and numerous vesicles.
Two case reports from 2025 describe individual patients. One reports a four-year-old female child born to second-degree consanguineous parents, presenting with delayed developmental milestones and failure to gain height. The other describes a case of DMC combined with Smith-McCort dysplasia. Both papers note that only about one hundred cases have been reported since 1962, with a mean incidence of 0.1 per million. A 2020 surgical report describes two siblings with DMC, odontoid hypoplasia, and atlantoaxial instability treated with Goel’s atlantoaxial fixation procedure; both had remarkable neurological recovery after stabilisation. The authors conclude that atlantoaxial instability is a potentially life-threatening condition in DMC and should be treated early.
No drug treatment for the underlying disease is mentioned in any of these abstracts. The 2003 genetic study provides no functional therapy. The surgical report addresses a specific complication, not the skeletal dysplasia or intellectual disability themselves. The 2025 case reports add no therapeutic data. What is missing: any preclinical or clinical trial of a pharmacological agent, any understanding of how Dymeclin loss might be corrected or compensated, any patient stratification beyond the genetic diagnosis, and any funding for drug development in a disease with an incidence of 0.1 per million.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Human Molecular Genetics · 2003 · 74 citations · open access
Mutations in a novel gene Dymeclin (FLJ20071) are responsible for Dyggve-Melchior-Clausen syndrome
AbstractDyggve-Melchior-Clausen syndrome (DMC) is a rare autosomal-recessive disorder, the gene for which maps to chromosome 18q21.1. DMC is characterized by the association of a spondylo-epi-metaphyseal dysplasia and mental retardation. Electron microscopic study of cutaneous cells of an affected child showed dilated rough endoplasmic reticulum, enlarged and aberrant vacuoles and numerous vesicles. As the etiology of the disorder is unknown, we have used a positional cloning strategy to identify the DMC gene. We detected seven deleterious mutations within a gene predicted from a human transcript (FLJ20071) in 10 DMC families. The mutations were nonsense mutations (R194X, R204X, L219X, Q483X), splice site or frameshift mutations (K626N+92aa to stop). The DMC gene transcript is widely distributed but appears abundant in chondrocytes and fetal brain. The predicted protein product of the DMC gene yields little insight into its likely function, showing no significant homology to any known protein family. However, the carboxy terminal end comprises a cluster of dileucine motifs, highly conserved across species. We conclude that DMC syndrome is consequent upon loss of function of a gene that we propose to name Dymeclin, which may have a role in process of intracellular digestion of proteins.
Turkish Neurosurgery · 2020 · 1 citations · open access
Atlantoaxial instability treated with posterior atlantoaxial fixation in two siblings with dyggve-melchior-clausen syndrome.
AbstractAIM: To discuss the rare association of atlantoaxial instability in patients with the Dyggve-Melchior-Clausen syndrome, a rare autosomal recessive disease characterized by progressive spondyloepimetaphyseal dysplasia and mild to severe mental retardation. MATERIAL AND METHODS: We report an uncommon association of two siblings with Dyggve-Melchior-Clausen syndrome, odontoid hypoplasia and atlantoaxial instability. Both the patients were treated with Goel?s atlantoaxial fixation procedure. RESULTS: The patients had a remarkable neurological recovery following the stabilization procedure. CONCLUSION: Atlantoaxial instability is a potentially life-threatening condition in patients with this syndrome and should be treated early with atlantoaxial stabilization. Recognition and treatment of atlantoaxial instability in patients with Dyggve-Melchior- Clausen syndrome can give gratifying results.
International Journal of Advanced Research · 2025 · 0 citations · open access
SKELETAL ANOMALIES AND BEYOND: A CASE REPORT OF DYGGVE MELCHIOR CLAUSEN DISEASE WITH SMITH MCCORT DYSPLASIA
AbstractDyggve Melchior Clausen (DMC) syndrome is an unusual form of uncommon autosomal recessive skeletal dysplasia.After its first occurrence in 1962, there has only been a hundred case reports to date with a mean incidence rate of0.1 per million.1 This article presents an account on a rare case report of Dyggve-MelchiorClausen disease combined with Smith Mccort Dysplasia.
GLOBAL JOURNAL FOR RESEARCH ANALYSIS · 2025 · 0 citations · open access
DYGGVE MELCHIOR CLAUSEN DISEASE- A RARE CASE REPORT
AbstractIntroduction: Dyggve-Melchior-Clausen syndrome (DMC) is a rare, autosomal recessive spondyloepimetaphyseal dysplasia marked by short stature, microcephaly, intellectual disability, and coarse facial features. A 4 years old female child born to a 2nd degree consanguinous married couple Case Report: was brought to RLJH with complaints of delayed developmental milestones and not gaining adequate height for age. Early Conclusion: diagnosis through clinical suspicion and genetic conrmation can improve long-term functional outcomes and guide genetic counseling
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
